Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference
Beam Therapeutics (Nasdaq: BEAM), a biotechnology company focused on developing precision genetic medicines through base editing, has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference. John Evans, the company's CEO, will engage in a fireside chat scheduled for Thursday, February 6, 2025, at 2:30 p.m. ET in New York.
The event will be accessible to interested parties through a live webcast on the investor section of Beam's website (www.beamtx.com). The presentation recording will remain available on the website for 60 days following the event.
Beam Therapeutics (Nasdaq: BEAM), un'azienda biotecnologica specializzata nello sviluppo di terapie genetiche di precisione attraverso l'editing alla base, ha annunciato la sua partecipazione alla prossima Guggenheim SMID Cap Biotech Conference. John Evans, CEO dell'azienda, parteciperà a una chiacchierata informale prevista per giovedì 6 febbraio 2025, alle 14:30 ET a New York.
L'evento sarà accessibile a tutti gli interessati tramite un webcast dal vivo nella sezione investitori del sito web di Beam (www.beamtx.com). La registrazione della presentazione rimarrà disponibile sul sito per 60 giorni dopo l'evento.
Beam Therapeutics (Nasdaq: BEAM), una empresa biotecnológica centrada en desarrollar medicamentos genéticos de precisión a través de la edición de bases, ha anunciado su participación en la próxima Guggenheim SMID Cap Biotech Conference. John Evans, el CEO de la compañía, participará en una charla informal programada para jueves 6 de febrero de 2025, a las 2:30 p.m. ET en Nueva York.
El evento será accesible para los interesados a través de un webcast en vivo en la sección de inversores del sitio web de Beam (www.beamtx.com). La grabación de la presentación estará disponible en el sitio por 60 días después del evento.
Beam Therapeutics (Nasdaq: BEAM)는 기초 편집을 통한 정밀 유전자 의약품 개발에 주력하는 생명공학 회사로, 다가오는 구겐하임 SMID Cap 생명공학 회의에 참여할 것이라고 발표했습니다. 존 에반스 CEO가 뉴욕에서 2025년 2월 6일 목요일 오후 2시 30분 ET에 예정된 대담에 참여합니다.
이벤트는 Beam 웹사이트의 투자자 섹션을 통해 실시간 웨비나로 관심 있는 모든 사람들이 접근할 수 있습니다 (www.beamtx.com). 발표 녹화 영상은 이벤트 이후 60일 동안 웹사이트에서 이용 가능합니다.
Beam Therapeutics (Nasdaq: BEAM), une entreprise de biotechnologie spécialisée dans le développement de médicaments génétiques de précision par le biais de l'édition de bases, a annoncé sa participation à la prochaine Guggenheim SMID Cap Biotech Conference. John Evans, le PDG de l'entreprise, participera à une discussion informelle prévue pour jeudi 6 février 2025, à 14h30 ET à New York.
L'événement sera accessible aux personnes intéressées via un webinaire en direct dans la section investisseurs du site Web de Beam (www.beamtx.com). L'enregistrement de la présentation restera disponible sur le site pendant 60 jours après l'événement.
Beam Therapeutics (Nasdaq: BEAM), ein biotechnologisches Unternehmen, das sich auf die Entwicklung präzisionsgenetischer Medikamente durch Basenbearbeitung konzentriert, hat seine Teilnahme an der bevorstehenden Guggenheim SMID Cap Biotech Conference bekannt gegeben. John Evans, der CEO des Unternehmens, wird an einem geplanten Fireside-Chat teilnehmen, der für Donnerstag, den 6. Februar 2025, um 14:30 Uhr ET in New York angesetzt ist.
Die Veranstaltung wird für interessierte Parteien über ein Live-Webcast im Investorensegment der Website von Beam (www.beamtx.com) zugänglich sein. Die Aufzeichnung der Präsentation bleibt für 60 Tage nach der Veranstaltung auf der Website verfügbar.
- None.
- None.
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025, at 2:30 p.m. ET in New York.
A live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contact:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
FAQ
When is Beam Therapeutics (BEAM) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How can investors watch Beam Therapeutics' (BEAM) presentation at the Guggenheim Conference?
How long will Beam Therapeutics' (BEAM) Guggenheim Conference presentation be available online?
What type of presentation will Beam Therapeutics (BEAM) give at the Guggenheim SMID Cap Conference?
